Functions of Shp2 in cancer

Journal of Cellular and Molecular Medicine

Volumn 19, Issue 9, 2015, Pages 2075-2083

  Zhang, Jie ^a   Zhang, Fei ^a   Niu, Ruifang ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Cancer; Cell proliferation; DNA damage; Drug resistance; Invasion and metastasis; Shp2

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FOCAL ADHESION KINASE; GLYCOGEN SYNTHASE KINASE 3BETA; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE SHP 2; STAT1 PROTEIN; STAT5 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURGERY; CELL PROLIFERATION; CHILDHOOD LEUKEMIA; DNA DAMAGE; DNA REPLICATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE MUTATION; HUMAN; LEOPARD SYNDROME; METASTASIS; NEOPLASM; NOONAN SYNDROME; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; TUMOR INVASION; TUMOR MICROENVIRONMENT; ANIMAL; DRUG RESISTANCE; ENZYMOLOGY; GENETICS; METABOLISM; MUTATION; PATHOLOGY;

ANIMALS; APOPTOSIS; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; HUMANS; MUTATION; NEOPLASMS; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11;

EID: 84940797434     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12618     Document Type: Article

References (96)

1. Feng GS, Shen R, Heng HH, et al. Receptor-binding, tyrosine phosphorylation and chromosome localization of the mouse SH2-containing phosphotyrosine phosphatase Syp Oncogene. 1994; 9: 1545-50.
2. Feng GS, Hui CC, Pawson T. SH2-containing phosphotyrosine phosphatase as a target of protein-tyrosine kinases. Science. 1993; 259: 1607-11.
3. Feng GS, Pawson T. Phosphotyrosine phosphatases with SH2 domains: regulators of signal transduction. Trends Genet. 1994; 10: 54-8.
4. Hof P, Pluskey S, Dhe-Paganon S, et al. Crystal structure of the tyrosine phosphatase SHP-2. Cell. 1998; 92: 441-50.
5. Bennett AM, Tang TL, Sugimoto S, et al. Protein-tyrosine-phosphatase SHPTP2 couples platelet-derived growth factor receptor beta to Ras. Proc Natl Acad Sci USA. 1994; 91: 7335-9.
6. Chan RJ, Feng GS. PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase. Blood. 2007; 109: 862-7.
7. Holgado-Madruga M, Emlet DR, Moscatello DK, et al. A Grb2-associated docking protein in EGF- and insulin-receptor signalling. Nature. 1996; 379: 560-4.
8. Kouhara H, Hadari YR, Spivak-Kroizman T, et al. A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway. Cell. 1997; 89: 693-702.
9. Xu D, Wang S, Yu WM, et al. A germline gain-of-function mutation in Ptpn11 (Shp-2) phosphatase induces myeloproliferative disease by aberrant activation of hematopoietic stem cells. Blood. 2010; 116: 3611-21.
10. Mohi MG, Neel BG. The role of Shp2 (PTPN11) in cancer. Curr Opin Genet Dev. 2007; 17: 23-30.
11. Zhou XD, Agazie YM. Inhibition of SHP2 leads to mesenchymal to epithelial transition in breast cancer cells. Cell Death Differ. 2008; 15: 988-96.
12. Aceto N, Sausgruber N, Brinkhaus H, et al. Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop. Nat Med. 2012; 18: 529-37.
13. Zhang X, Lavoie G, Fort L, et al. Gab2 phosphorylation by RSK inhibits Shp2 recruitment and cell motility. Mol Cell Biol. 2013; 33: 1657-70.
14. Mariotto S, Ciampa AR, de Prati AC, et al. Aqueous extract of Arbutus unedo inhibits STAT1 activation in human breast cancer cell line MDA-MB-231 and human fibroblasts through SHP2 activation. Med Chem. 2008; 4: 219-28.
15. Zhou X, Agazie YM. Molecular mechanism for SHP2 in promoting HER2-induced signaling and transformation. J Biol Chem. 2009; 284: 12226-34.
16. Lee IO, Kim JH, Choi YJ, et al. Helicobacter pylori CagA phosphorylation status determines the gp130-activated SHP2/ERK and JAK/STAT signal transduction pathways in gastric epithelial cells. J Biol Chem. 2010; 285: 16042-50.
17. Lazzara MJ, Lane K, Chan R, et al. Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutations. Cancer Res. 2010; 70: 3843-50.
18. Xie H, Huang S, Li W, et al. Upregulation of Src homology phosphotyrosyl phosphatase 2 (Shp2) expression in oral cancer and knockdown of Shp2 expression inhibit tumor cell viability and invasion in vitro. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014; 117: 234-42.
19. Gu J, Han T, Ma RH, et al. SHP2 promotes laryngeal cancer growth through the Ras/Raf/Mek/Erk pathway and serves as a prognostic indicator for laryngeal cancer. Int J Oncol. 2014; 44: 481-90.
20. Meng F, Zhao X, Zhang S. Expression and significance of SHP-2 in human papillomavirus infected cervical cancer. J Huazhong Univ Sci Technolog Med Sci. 2012; 32: 247-51.
21. Meng F, Zhao X, Zhang S. SHP-2 phosphatase promotes cervical cancer cell proliferation through inhibiting interferon-beta production. J Obstet Gynaecol Res. 2013; 39: 272-9.
22. Bard-Chapeau EA, Li S, Ding J, et al. Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis. Cancer Cell. 2011; 19: 629-39.
23. Yang W, Wang J, Moore DC, et al. Ptpn11 deletion in a novel progenitor causes metachondromatosis by inducing hedgehog signalling. Nature. 2013; 499: 491-5.
24. Lu W, Gong D, Bar-Sagi D, et al. Site-specific incorporation of a phosphotyrosine mimetic reveals a role for tyrosine phosphorylation of SHP-2 in cell signaling. Mol Cell. 2001; 8: 759-69.
25. Agazie YM, Movilla N, Ischenko I, et al. The phosphotyrosine phosphatase SHP2 is a critical mediator of transformation induced by the oncogenic fibroblast growth factor receptor 3. Oncogene. 2003; 22: 6909-18.
26. Maroun CR, Naujokas MA, Holgado-Madruga M, et al. The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Mol Cell Biol. 2000; 20: 8513-25.
27. Noguchi T, Matozaki T, Horita K, et al. Role of SH-PTP2, a protein-tyrosine phosphatase with Src homology 2 domains, in insulin-stimulated Ras activation. Mol Cell Biol. 1994; 14: 6674-82.
28. Paruchuri V, Prasad A, McHugh K, et al. S100A7-downregulation inhibits epidermal growth factor-induced signaling in breast cancer cells and blocks osteoclast formation. PLoS ONE. 2008; 3: e1741.
29. Miura K, Wakayama Y, Tanino M, et al. Involvement of EphA2-mediated tyrosine phosphorylation of Shp2 in Shp2-regulated activation of extracellular signal-regulated kinase. Oncogene. 2013; 32: 5292-301.
30. Ahmed Z, Lin CC, Suen KM, et al. Grb2 controls phosphorylation of FGFR2 by inhibiting receptor kinase and Shp2 phosphatase activity. J Cell Biol. 2013; 200: 493-504.
31. Tseng PC, Huang WC, Chen CL, et al. Regulation of SHP2 by PTEN/AKT/GSK-3beta signaling facilitates IFN-gamma resistance in hyperproliferating gastric cancer. Immunobiology. 2012; 217: 926-34.
32. Diaz ME, Gonzalez L, Miquet JG, et al. Growth hormone modulation of EGF-induced PI3K-Akt pathway in mice liver. Cell Signal. 2012; 24: 514-23.
33. Sha F, Gencer EB, Georgeon S, et al. Dissection of the BCR-ABL signaling network using highly specific monobody inhibitors to the SHP2 SH2 domains. Proc Natl Acad Sci USA. 2013; 110: 14924-9.
34. Vogel W, Ullrich A. Multiple in vivo phosphorylated tyrosine phosphatase SHP-2 engages binding to Grb2 via tyrosine 584. Cell Growth Differ. 1996; 7: 1589-97.
35. Zhang W, Chan RJ, Chen H, et al. Negative regulation of Stat3 by activating PTPN11 mutants contributes to the pathogenesis of Noonan syndrome and juvenile myelomonocytic leukemia. J Biol Chem. 2009; 284: 22353-63.
36. Gough DJ, Corlett A, Schlessinger K, et al. Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science. 2009; 324: 1713-6.
37. Wang YQ, Zhang F, Tian R, et al. Tyrosine 23 phosphorylation of annexin A2 promotes proliferation, invasion, and Stat3 phosphorylation in the nucleus of human breast cancer SK-BR-3 cells. Cancer Biol Med. 2012; 9: 248-53.
38. Tartaglia M, Mehler EL, Goldberg R, et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet. 2001; 29: 465-8.
39. Tartaglia M, Gelb BD. Germ-line and somatic PTPN11 mutations in human disease. Eur J Med Genet. 2005; 48: 81-96.
40. Bennett AM, Hausdorff SF, O'Reilly AM, et al. Multiple requirements for SHPTP2 in epidermal growth factor-mediated cell cycle progression. Mol Cell Biol. 1996; 16: 1189-202.
41. Conti E, Dottorini T, Sarkozy A, et al. A novel PTPN11 mutation in LEOPARD syndrome. Hum Mutat. 2003; 21: 654.
42. Tajan M, Batut A, Cadoudal T, et al. LEOPARD syndrome-associated SHP2 mutation confers leanness and protection from diet-induced obesity. Proc Natl Acad Sci USA. 2014; 111: E4494-503.
43. Fragale A, Tartaglia M, Wu J, et al. Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation. Hum Mutat. 2004; 23: 267-77.
44. Bentires-Alj M, Paez JG, David FS, et al. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res. 2004; 64: 8816-20.
45. Schneeberger VE, Luetteke N, Ren Y, et al. SHP2E76K mutant promotes lung tumorigenesis in transgenic mice. Carcinogenesis. 2014; 35: 1717-25.
46. Hellmuth K, Grosskopf S, Lum CT, et al. Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput docking. Proc Natl Acad Sci USA. 2008; 105: 7275-80.
47. Edwards MA, Crombie K, Schramm C, Krenz M. The Q510E mutation in Shp2 perturbs heart valve development by increasing cell migration. J Appl Physiol. 2014; 118: 124-31.
48. Oishi K, Gaengel K, Krishnamoorthy S, et al. Transgenic Drosophila models of Noonan syndrome causing PTPN11 gain-of-function mutations. Hum Mol Genet. 2006; 15: 543-53.
49. Sausgruber N, Coissieux MM, Britschgi A, et al. Tyrosine phosphatase SHP2 increases cell motility in triple-negative breast cancer through the activation of SRC-family kinases. Oncogene. 2014; 34: 2272-8.
50. Fernandis AZ, Prasad A, Band H, et al. Regulation of CXCR4-mediated chemotaxis and chemoinvasion of breast cancer cells. Oncogene. 2004; 23: 157-67.
51. Hartman ZR, Schaller MD, Agazie YM. The tyrosine phosphatase SHP2 regulates focal adhesion kinase to promote EGF-induced lamellipodia persistence and cell migration. Mol Cancer Res. 2013; 11: 651-64.
52. Zhou X, Coad J, Ducatman B, et al. SHP2 is up-regulated in breast cancer cells and in infiltrating ductal carcinoma of the breast, implying its involvement in breast oncogenesis. Histopathology. 2008; 53: 389-402.
53. Wang HC, Chiang WF, Huang HH, et al. Src-homology 2 domain-containing tyrosine phosphatase 2 promotes oral cancer invasion and metastasis. BMC Cancer. 2014; 14: 442.
54. Tang C, Luo D, Yang H, et al. Expression of SHP2 and related markers in non-small cell lung cancer: a tissue microarray study of 80 cases. Appl Immunohistochem Mol Morphol. 2013; 21: 386-94.
55. Tang C, Zhou X, Yang H, et al. Expression and its clinical significance of SHP2 in non-small cell lung cancer. Zhongguo Fei Ai Za Zhi. 2010; 13: 98-101.
56. Li S, Wang L, Zhao Q, et al. SHP2 Positively Regulates TGFbeta1-induced Epithelial-mesenchymal Transition Modulated by Its Novel Interacting Protein Hook1. J Biol Chem. 2014; 289: 34152-60.
57. Dong S, Li FQ, Zhang Q, et al. Expression and clinical significance of SHP2 in gastric cancer. J Int Med Res. 2012; 40: 2083-9.
58. Voena C, Conte C, Ambrogio C, et al. The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration. Cancer Res. 2007; 67: 4278-86.
59. Yang X, Dutta U, Shaw LM. SHP2 mediates the localized activation of Fyn downstream of the alpha6beta4 integrin to promote carcinoma invasion. Mol Cell Biol. 2010; 30: 5306-17.
60. Pan YR, Cho KH, Lee HH, et al. Protein tyrosine phosphatase SHP2 suppresses podosome rosette formation in Src-transformed fibroblasts. J Cell Sci. 2013; 126: 657-66.
61. Chauhan D, Pandey P, Hideshima T, et al. SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. J Biol Chem. 2000; 275: 27845-50.
62. Anderson KC. Multiple Myeloma. Advances in disease biology: therapeutic implications. Semin Hematol. 2001; 38: 6-10.
63. Xu R, Yu Y, Zheng S, et al. Overexpression of Shp2 tyrosine phosphatase is implicated in leukemogenesis in adult human leukemia. Blood. 2005; 106: 3142-9.
64. Konieczna I, Horvath E, Wang H, et al. Constitutive activation of SHP2 in mice cooperates with ICSBP deficiency to accelerate progression to acute myeloid leukemia. J Clin Investig. 2008; 118: 853-67.
65. Yang W, Klaman LD, Chen B, et al. An Shp2/SFK/Ras/Erk signaling pathway controls trophoblast stem cell survival. Dev Cell. 2006; 10: 317-27.
66. Ralston A, Rossant J. How signaling promotes stem cell survival: trophoblast stem cells and Shp2. Dev Cell. 2006; 10: 275-6.
67. Ren Y, Chen Z, Chen L, et al. Shp2E76K mutant confers cytokine-independent survival of TF-1 myeloid cells by up-regulating Bcl-XL. J Biol Chem. 2007; 282: 36463-73.
68. Yang Z, Li Y, Yin F, et al. Activating PTPN11 mutants promote hematopoietic progenitor cell-cycle progression and survival. Exp Hematol. 2008; 36: 1285-96.
69. Cheng HL, Su SJ, Huang LW, et al. Arecoline induces HA22T/VGH hepatoma cells to undergo anoikis - involvement of STAT3 and RhoA activation. Mol Cancer. 2010; 9: 126.
70. Blechacz BR, Smoot RL, Bronk SF, et al. Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2. Hepatology. 2009; 50: 1861-70.
71. Morales LD, Casillas Pavon EA, Shin JW, et al. Protein tyrosine phosphatases PTP-1B, SHP-2, and PTEN facilitate Rb/E2F-associated apoptotic signaling. PLoS ONE. 2014; 9: e97104.
72. Yu L, Min W, He Y, et al. JAK2 and SHP2 reciprocally regulate tyrosine phosphorylation and stability of proapoptotic protein ASK1. The Journal of biological chemistry. 2009; 284: 13481-8.
73. Chan G, Cheung LS, Yang W, et al. Essential role for Ptpn11 in survival of hematopoietic stem and progenitor cells. Blood. 2011; 117: 4253-61.
74. Nabinger SC, Chan RJ. Shp2 function in hematopoietic stem cell biology and leukemogenesis. Curr Opin Hematol. 2012; 19: 273-9.
75. Zhang X, Zhang Y, Tao B, et al. Loss of Shp2 in alveoli epithelia induces deregulated surfactant homeostasis, resulting in spontaneous pulmonary fibrosis. FASEB J. 2012; 26: 2338-50.
76. Rafiq K, Kolpakov MA, Abdelfettah M, et al. Role of protein-tyrosine phosphatase SHP2 in focal adhesion kinase down-regulation during neutrophil cathepsin G-induced cardiomyocytes anoikis. J Biol Chem. 2006; 281: 19781-92.
77. Amin AR, Thakur VS, Paul RK, et al. SHP-2 tyrosine phosphatase inhibits p73-dependent apoptosis and expression of a subset of p53 target genes induced by EGCG. Proc Natl Acad Sci USA. 2007; 104: 5419-24.
78. Lennartsson J, Burovic F, Witek B, et al. Erk 5 is necessary for sustained PDGF-induced Akt phosphorylation and inhibition of apoptosis. Cell Signal. 2010; 22: 955-60.
79. Courboulin A, Paulin R, Giguere NJ, et al. Role for miR-204 in human pulmonary arterial hypertension. J Exp Med. 2011; 208: 535-48.
80. Li J, Reed SA, Johnson SE. Hepatocyte growth factor (HGF) signals through SHP2 to regulate primary mouse myoblast proliferation. Exp Cell Res. 2009; 315: 2284-92.
81. Zhu Y, Park J, Hu X, et al. Control of oligodendrocyte generation and proliferation by Shp2 protein tyrosine phosphatase. Glia. 2010; 58: 1407-14.
82. + cells. Blood. 2011; 118: 1504-15.
83. Furcht CM, Buonato JM, Skuli N, et al. Multivariate signaling regulation by SHP2 differentially controls proliferation and therapeutic response in glioma cells. J Cell Sci. 2014; 127: 3555-67.
84. Hu Z, Fang H, Wang X, et al. Overexpression of SHP2 tyrosine phosphatase promotes the tumorigenesis of breast carcinoma. Oncol Rep. 2014; 32: 205-12.
85. Rose DW, Xiao S, Pillay TS, et al. Prolonged vs transient roles for early cell cycle signaling components. Oncogene. 1998; 17: 889-99.
86. Sturla LM, Zinn PO, Ng K, et al. Src homology domain-containing phosphatase 2 suppresses cellular senescence in glioblastoma. Br J Cancer. 2011; 105: 1235-43.
87. Buet D, Gallais I, Lauret E, et al. Cotargeting signaling pathways driving survival and cell cycle circumvents resistance to Kit inhibitors in leukemia. Blood. 2012; 119: 4228-41.
88. Peng G, Cao RB, Li YH, et al. Alterations of cell cycle control proteins SHP1/2, p16, CDK4 and cyclin D1 in radioresistant nasopharyngeal carcinoma cells. Mol Med Rep. 2014; 10: 1709-16.
89. Tsang YH, Han X, Man WY, et al. Novel functions of the phosphatase SHP2 in the DNA replication and damage checkpoints. PLoS ONE. 2012; 7: e49943.
90. Kathpalia VP, Mussak EN, Chow SS, et al. Genome-wide transcriptional profiling in human squamous cell carcinoma of the skin identifies unique tumor-associated signatures. J Dermatol. 2006; 33: 309-18.
91. Zhang L, Yang Z, Ma A, et al. Growth arrest and DNA damage 45G down-regulation contributes to Janus kinase/signal transducer and activator of transcription 3 activation and cellular senescence evasion in hepatocellular carcinoma. Hepatology. 2014; 59: 178-89.
92. Xu J, Zeng LF, Shen W, et al. Targeting SHP2 for EGFR inhibitor resistant non-small cell lung carcinoma. Biochem Biophys Res Commun. 2013; 439: 586-90.
93. Liu W, Yu B, Xu G, et al. Identification of cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11). J Med Chem. 2013; 56: 7212-21.
94. Duan YQ, Ma Y, Wang XJ, et al. Design potential selective inhibitors for treating cancer by targeting the Src homology 2 (SH2) domain-containing phosphatase 2 (Shp2) with core hopping approach. Protein Pept Lett. 2014; 21: 556-63.
95. Sharma N, Everingham S, Zeng LF, et al. Oncogenic KIT-induced aggressive systemic mastocytosis requires SHP2/PTPN11 phosphatase for disease progression in mice. Oncotarget. 2014; 5: 6130-41.
96. Yu B, Liu W, Yu WM, et al. Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies. Mol Cancer Ther. 2013; 12: 1738-48.